Drugs / FID007
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06332092 Comparator | Apr 2024 → Dec 2025 overdue | head and neck squamous cell carcinoma | Fulgent Pharma LLC. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FID007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06332092 ↗ |
| Route | Intravenous | “FID007 via IV infusion” NCT06332092 ↗ |